Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 5/20 | 0.48 |
| ▸ | FEN1 | P39748 | 5/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13243061 | 1.00 | ALOX5AP (0.48) | ALOX5APFEN1MAP2K1MGLLPARP1 | |
| SCHEMBL30198727 | 0.80 | CPS1 (0.49) | ALOX5APFEN1MEN1KMT2APIK3CA | |
| SCHEMBL21245854 | 0.80 | CPS1 (0.49) | ALOX5APFEN1MEN1KMT2APIK3CA | |
| SCHEMBL10126547 | 0.78 | TSHR (0.59) | PARP1MEN1KMT2AALDH1A1PIK3CA | |
| SCHEMBL2993890 | 0.76 | MGLL (0.55) | MGLLPDK2 | |
| SCHEMBL19144451 | 0.76 | MGLL (0.55) | MGLLPDK2 | |
| SCHEMBL3400169 | 0.75 | MEN1 (0.57) | PARP1MEN1KMT2A | |
| SCHEMBL1392181 | 0.75 | MAPT (0.57) | ALOX5APFEN1PARP1PIK3CAMTOR | |
| SCHEMBL14894817 | 0.74 | MGLL (0.57) | MGLLPDK2RAB9A | |
| SCHEMBL14163236 | 0.74 | PARP1 (0.48) | MGLLPARP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7601725-B2 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601725-B2 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | AURKA, AURKB, AURKC | ALOX5AP 3577/4885FEN1 1007/4885MAP2K1 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.